Emmes Europe

Message from Pavel Marek, Managing Director

Pavel Marek

Emmes’ operations in Europe have proudly contributed to the advancement of medical research for almost two decades. With the 2020 acquisition of Neox s.r.o., a European-based CRO, we have expanded into 18 countries on the continent and the UK. A few months later, Emmes acquired Orphan Reach, a UK based CRO dedicated to clinical research in rare diseases. This local knowledge and niche expertise enable optimal country selection for clinical trials, rapid enrollment, tailored monitoring, and regulatory expertise.

neox orphanreach

Together, we create Emmes Europe, and our skills are bringing significant capabilities and growth opportunities to public health and biopharmaceutical institutions.

With a commitment to quality in everything we do, clients rely on Emmes Europe for a wide range of services and our unique understanding of the European market. Our footprint in Europe also provides our clients access to motivated, well-educated PIs, CRAs and an unusually high patient compliance rate.
Explore Services

Emmes provides clinical research services supported by software solutions and deep therapeutic area & biostatistical expertise

Drug and Medical Device Development Services

With extensive experience in multiple therapeutic areas including oncology, cardiology, neurology, and gastroenterology, Emmes Europe provides a wide array of clinical research services. We support our clients in a number of ways ranging from Phase I-IV clinical trials, medical writing, bio-equivalence studies, site contracting, project management, as well as clinical and medical monitoring. We also serve as consultants to clients on new European legislation related to medical devices and in vitro diagnostics.

Explore Medical Devices

Bioinformatics-Analysis-Solutions

Orphan and Rare Disease Research

With approximately 7,000 rare diseases affecting 300 million people worldwide, clinical trial research in rare diseases continues to be a top priority for Emmes and many of our clients. While only 5% of rare diseases have an approved treatment, Emmes strives to be at the forefront of groundbreaking research for these small, yet collectively large populations in order to increase the treatments available within the rare disease space.

Our recent acquisition of Orphan Reach, a rare CRO, helps to establish us as an industry leader in clinical research for orphan and rare diseases. Together, we combine 40 years of research and data experience with a specialized team whose reputation spans across 60+ rare disease trials and 50 biopharma clients throughout the world.

This new and unique offering drives our expert rare disease team to provide continued, seamless, high quality support to biopharmaceutical companies throughout any stage of the orphan product lifecycle.

Explore Orphan and Rare Disease Research

Emmes provides clinical research services supported by software solutions and deep therapeutic area & biostatistical expertise

Data Management & Biostatistics

From database design and electronic data capture to statistical planning and support, Emmes offers a team of experienced data managers and biostatisticians to support all areas of your research. With expertise in study design, hypothesis testing, randomization, sample size and power calculations, analysis and reporting, our focus is on data integrity and study deliverables of the highest quality.

Explore Biostatistics

Bioinformatics-Analysis-Solutions

Site Management and Patient Recruitment

Emmes Europe's local knowledge of clinical trial sites and EU regulations can help you identify, select, recruit, and activate the sites and patients required to move your clinical trial forward. Our clinical monitors are thoroughly trained to perform site monitoring as required by GCP and other relevant regulations. We offer a full range of services in the area, including site contracting, data monitoring, pharmacovigilance and more. We can help you oversee data collection, review case report forms and documentation, resolve data queries, and ensure regulatory compliance.

Hematology Experience

Phase IV and Post-Marketing

At Emmes, we understand the complementary relationship of clinical evidence and product value. Whether you are seeking to demonstrate value to regulators, payers, clinicians or patients, our team of experts in real-world evidence and real-world data can support you throughout the clinical development lifecycle and beyond. As your product seeks market authorization, we can enhance your go-to-market strategy by employing our expertise in clinical, pharmacological, epidemiological and statistical analysis. From supporting post-marketing commitments to Phase IV studies and registries, Emmes is here to help improve your product’s success.

Visit Emmes Locations